Sugi Predict

Sugi Predict / Compounds / SCHEMBL1103653

SCHEMBL1103653

SCHEMBL1103653

Cc1ccc2c(-c3ccc4ccccc4c3)c3cnccc3c(-c3ccc4c(c3)C(C)(C)c3ccccc3-4)c2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 2/20 0.36
▸ QPCT Q16769 2/20 0.36
▸ CYP17A1 P05093 1/20 0.34
▸ CYP19A1 P11511 1/20 0.34
▸ CYP11B1 P15538 1/20 0.34
▸ CYP11B2 P19099 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ CCNC P24863 7/20 0.32
▸ CDK8 P49336 7/20 0.32
▸ SLC22A12 Q96S37 1/20 0.32
▸ MAPK14 Q16539 1/20 0.32
▸ PDK2 Q15119 2/20 0.32
▸ MAPK9 P45984 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103622 0.94 PDK2 (0.36) CYP17A1ALDH1A1KDM4EMEN1LMNA
SCHEMBL1105443 0.93 TDO2 (0.35) GSK3BQPCTCYP17A1CYP19A1CYP11B1
SCHEMBL1103634 0.93 CYP17A1 (0.39) CYP17A1CYP19A1CYP11B1CYP11B2CCNC
SCHEMBL1103643 0.93 CYP17A1 (0.39) CYP17A1CYP19A1CYP11B1CYP11B2CCNC
SCHEMBL1103676 0.93 CYP17A1 (0.39) CYP17A1CYP19A1CYP11B1CYP11B2CCNC
SCHEMBL10072718 0.92 CYP17A1 (0.37) GSK3BQPCTCYP17A1CYP19A1CYP11B1
SCHEMBL1102725 0.92 CYP11B1 (0.39) CYP17A1CYP19A1CYP11B1CYP11B2CCNC
SCHEMBL1103654 0.90 KDR (0.35) ALDH1A1KDM4EMEN1LMNAMAPT
SCHEMBL1103688 0.90 CYP17A1 (0.40) CYP17A1CYP19A1CYP11B1CYP11B2CCNC
SCHEMBL1103682 0.90 CYP11B2 (0.40) CYP17A1CYP19A1CYP11B1CYP11B2CCNC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 GSK3B 3423/4885QPCT 4324/4885CYP17A1 2034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.